Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma

Recently, immunotherapy based on blocking immune checkpoints with programmed death‐1 (PD‐1) or PD‐ligand 1 (PD‐L1) Abs has been introduced for the treatment of advanced clear cell renal cell carcinoma (ccRCC), especially tumors resistant to vascular endothelial growth factor‐tyrosine kinase inhibito...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Mikami, Shuji, Mizuno, Ryuichi, Kondo, Tsunenori, Shinohara, Nobuo, Nonomura, Norio, Ozono, Seiichiro, Eto, Masatoshi, Tatsugami, Katsunori, Takayama, Tatsuya, Matsuyama, Hideyasu, Kishida, Takeshi, Oya, Mototsugu
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6550131/
https://ncbi.nlm.nih.gov/pubmed/30972888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14019
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars